Successful Treatment of Non-small Cell Lung Cancer with Gefitinib after Severe Erlotinib-related Hepatotoxicity
Authors:
Open Access
- 1 January 2012
- journal article
- case report
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 51 (4) , 431-434
Abstract
Gefitinib and erlotinib are first-generation small molecular inhibitors of EGFR tyrosine kinase activity. To the best of our knowledge, to date, two reports have stated that patients with NSCLC who develop severe hepatotoxicity secondary to gefitinib treatment can be safely switched to erlotinib. However, the reverse situation has not been reported. Here, we present the first case with non-small cell lung cancer harboring EGFR mutation who developed grade 3/4 hepatotoxicity after initiation of erlotinib, which resolved when therapy was changed to gefitinib. As far as we know, this is the first report showing the efficacy of gefitinib for a non-small cell lung cancer patient who developed severe hepatotoxicity while under erlotinib therapy.Keywords
This publication has 13 references indexed in Scilit:
- Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicityLung Cancer, 2010
- Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung CancerJournal of Thoracic Oncology, 2010
- Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to GefitinibJournal of Thoracic Oncology, 2009
- Three cases of severe hepatic impairment caused by erlotinibBritish Journal of Clinical Pharmacology, 2009
- Fulminant Hepatic Failure Secondary to ErlotinibClinical Gastroenterology and Hepatology, 2007
- Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 EnzymesClinical Cancer Research, 2007
- Whole-Brain Radiotherapy in the Management of Brain MetastasisJournal of Clinical Oncology, 2006
- METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERSDrug Metabolism and Disposition, 2006
- Drug-Related HepatotoxicityNew England Journal of Medicine, 2006
- Current Management of Brain Metastases, With a Focus on Systemic OptionsJournal of Clinical Oncology, 2005